Fuwai Central China Cardiovascular Hospital Becomes First to Offer Advanced Robotic Treatment for Heart Rhythm Disorders in Central China
January 27 2022 - 9:07AM
Stereotaxis (NYSE: STXS), the global leader in innovative robotic
technologies for the treatment of cardiac arrhythmias, announces
that Fuwai Central China Cardiovascular Hospital has become the
first in central China to establish a robotic electrophysiology
program with installation of Stereotaxis’ Robotic Magnetic
Navigation technology. Chief physicians for arrhythmia treatment,
Dr. Chen Ke and Dr. Song Weifeng, successfully performed their
first robotic cardiac ablation procedure, treating a patient who
suffered from a complex ventricular arrhythmia.
“I am very proud of our team for successfully
completing our first robotic ablation procedure in under one hour,
an effort that would have had added risk and taken much longer with
traditional, manual methods,” said Fuwai Central China
Cardiovascular Hospital Director of Arrhythmia, Professor Wang
Xianqing. “Robotic Magnetic Navigation is the most advanced
electrophysiology assisted catheter operating system in the
world.”
Tens of millions of individuals worldwide suffer
from arrhythmias – abnormal heart rhythms that result when the
heart beats too quickly, too slowly, or with an irregular pattern.
When left untreated, arrhythmias may significantly increase the
risk of stroke, heart failure, and sudden cardiac arrest. Robotic
Magnetic Navigation introduces the benefits of robotic precision
and safety to cardiac ablation, a common, minimally invasive
procedure to treat arrhythmias. Robotic cardiac ablation is
performed using a soft magnetic catheter navigated inside the heart
by a physician seated at a computer cockpit. The physician
navigates the catheter using precise, robotically actuated magnets
positioned on either side of the patient.
“Our new robotic electrophysiology program helps
us achieve our mission of providing the safest and most effective
treatment options for patients suffering from cardiac arrhythmias,”
said Hospital President, Professor Gao Chuanyu. “We are thrilled by
the initial success and see cardiac ablation as just the beginning
of the potential for robotically assisted interventional procedures
with Stereotaxis technology.”
“We are delighted by the success of Fuwai
Central China Cardiovascular Hospital,” said David Fischel,
chairman and CEO of Stereotaxis. “We applaud their leadership and
look forward to supporting their continued efforts to help many
more patients as they build a preeminent heart rhythm program.”
About StereotaxisStereotaxis
(NYSE: STXS) is a pioneer and global leader in innovative surgical
robotics for minimally invasive endovascular intervention. Its
mission is the discovery, development and delivery of robotic
systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
expand access to minimally invasive therapy, and enhance the
productivity, connectivity, and intelligence in the operating room.
Stereotaxis technology has been used to treat over 100,000 patients
across the United States, Europe, Asia, and elsewhere. For more
information, please visit www.stereotaxis.com
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Stereotaxis Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2023 to Apr 2024